{"id":9662,"date":"2026-03-18T06:23:26","date_gmt":"2026-03-17T22:23:26","guid":{"rendered":"https:\/\/regask.com\/?p=9662"},"modified":"2026-03-18T06:23:26","modified_gmt":"2026-03-17T22:23:26","slug":"le-cde-chinois-publie-des-recommandations-provisoires-sur-les-essais-cliniques-des-vaccins-contre-la-grippe","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/","title":{"rendered":"Le CDE chinois publie des recommandations provisoires sur les essais cliniques\u2026"},"content":{"rendered":"<p><span data-contrast=\"auto\">Sur\u00a0<\/span><b><span data-contrast=\"auto\">11 mars 2026<\/span><\/b><span data-contrast=\"auto\">, le\u00a0<\/span><b><span data-contrast=\"auto\">Centre d&#039;\u00e9valuation des m\u00e9dicaments (CDE)<\/span><\/b><span data-contrast=\"auto\">\u00a0a publi\u00e9 un\u00a0<\/span><b><span data-contrast=\"auto\">orientations provisoires sur les essais cliniques des vaccins contre la grippe<\/span><\/b><span data-contrast=\"auto\">, d\u00e9crivant les attentes r\u00e9glementaires actualis\u00e9es concernant le d\u00e9veloppement clinique et l&#039;\u00e9valuation des vaccins en Chine.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Les lignes directrices \u00e9tablissent\u00a0<\/span><b><span data-contrast=\"auto\">exigences techniques relatives \u00e0 la conception, \u00e0 la r\u00e9alisation et \u00e0 l&#039;\u00e9valuation des essais cliniques<\/span><\/b><span data-contrast=\"auto\">, visant \u00e0 soutenir la recherche scientifique et la coh\u00e9rence r\u00e9glementaire dans le d\u00e9veloppement des vaccins contre la grippe. Elle s&#039;applique aux organisations impliqu\u00e9es dans\u00a0<\/span><b><span data-contrast=\"auto\">Recherche et d\u00e9veloppement clinique, contr\u00f4le de la qualit\u00e9 et enregistrement r\u00e9glementaire<\/span><\/b><span data-contrast=\"auto\">\u00a0des vaccins contre la grippe et sont entr\u00e9s en vigueur imm\u00e9diatement apr\u00e8s leur publication.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<div class=\"row\"  id=\"row-1304335052\">\n\n\t<div id=\"col-345218614\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-878783496\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-878783496 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>D\u00e9tails de la mise \u00e0 jour<\/h2>\n\t<div id=\"gap-1842732121\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1842732121 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Les nouvelles directives introduisent\u00a0<\/span><b><span data-contrast=\"auto\">normes techniques r\u00e9gissant les essais cliniques des vaccins contre la grippe<\/span><\/b><span data-contrast=\"auto\">, avec des exigences qui s&#039;appliquent \u00e0 toutes les \u00e9tudes pertinentes men\u00e9es en Chine \u00e0 partir de\u00a0<\/span><b><span data-contrast=\"auto\">\u00c0 compter du 11 mars 2026<\/span><\/b><span data-contrast=\"auto\">. Ces normes visent \u00e0 garantir que le d\u00e9veloppement et l&#039;\u00e9valuation des vaccins respectent des exigences r\u00e9glementaires coh\u00e9rentes.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Le document \u00e9nonce les exigences relatives \u00e0\u00a0<\/span><b><span data-contrast=\"auto\">m\u00e9thodologie des essais cliniques<\/span><\/b><span data-contrast=\"auto\">, en fournissant des indications sur la mani\u00e8re dont les \u00e9tudes sur les vaccins contre la grippe devraient \u00eatre structur\u00e9es pour r\u00e9pondre aux normes d&#039;examen r\u00e9glementaire.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Il \u00e9tablit \u00e9galement des attentes concernant\u00a0<\/span><b><span data-contrast=\"auto\">proc\u00e9dures de surveillance de la s\u00e9curit\u00e9<\/span><\/b><span data-contrast=\"auto\">, en veillant \u00e0 ce que les essais vaccinaux assurent une surveillance constante de la s\u00e9curit\u00e9 des participants tout au long de la p\u00e9riode d&#039;\u00e9tude.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">De plus, les directives abordent\u00a0<\/span><b><span data-contrast=\"auto\">pratiques de collecte de donn\u00e9es<\/span><\/b><span data-contrast=\"auto\">, soulignant la n\u00e9cessit\u00e9 de g\u00e9n\u00e9rer des donn\u00e9es cliniques structur\u00e9es et fiables lors des essais vaccinaux.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Enfin, il sp\u00e9cifie\u00a0<\/span><b><span data-contrast=\"auto\">obligations de d\u00e9claration<\/span><\/b><span data-contrast=\"auto\">, pr\u00e9cisant comment les r\u00e9sultats des essais cliniques et les informations relatives \u00e0 la s\u00e9curit\u00e9 doivent \u00eatre document\u00e9s et soumis aux autorit\u00e9s r\u00e9glementaires au cours du processus de d\u00e9veloppement du vaccin.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-345218614 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1202953313\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Date d&#039;entr\u00e9e en vigueur<\/h2>\n\t<div id=\"gap-1532196233\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1532196233 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Les directives provisoires sont devenues <strong>en vigueur \u00e0 compter du 11 mars 2026 <\/strong>et s&#039;applique \u00e0 tous<strong> Nouveaux essais cliniques et essais cliniques en cours sur les vaccins contre la grippe, initi\u00e9s \u00e0 compter de cette date en Chine. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1202953313 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-595273305\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Pourquoi c&#039;est important<\/h2>\n\t<div id=\"gap-281927700\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-281927700 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>La mise \u00e0 jour introduit <strong>des normes techniques claires pour les essais cliniques des vaccins contre la grippe,<\/strong> Renforcer l&#039;harmonisation r\u00e9glementaire des activit\u00e9s de d\u00e9veloppement des vaccins en Chine. En clarifiant les attentes concernant<strong> m\u00e9thodologie des essais, surveillance de la s\u00e9curit\u00e9 et rapports,<\/strong> Ces lignes directrices favorisent une \u00e9valuation r\u00e9glementaire plus coh\u00e9rente tout en contribuant \u00e0 r\u00e9duire l&#039;incertitude pour les organismes menant des activit\u00e9s de recherche et de d\u00e9veloppement de vaccins.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-595273305 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1024040436\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>\u00c0 qui cela s&#039;adresse-t-il ?<\/h2>\n\t<div id=\"gap-1485941629\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1485941629 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Cette mise \u00e0 jour r\u00e9glementaire concerne <strong>\u00c9quipes des affaires r\u00e9glementaires, de la recherche et du d\u00e9veloppement clinique, de l&#039;assurance qualit\u00e9 et de la s\u00e9curit\u00e9<\/strong> impliqu\u00e9s dans le d\u00e9veloppement du vaccin contre la grippe, notamment <strong>Fabricants et importateurs nationaux sollicitant une autorisation de mise sur le march\u00e9 en Chine. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1024040436 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1717019643\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Prochaines \u00e9tapes<\/h2>\n\t<div id=\"gap-1611261254\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1611261254 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Les organisations qui d\u00e9veloppent des vaccins contre la grippe devraient\u00a0<\/span><b><span data-contrast=\"auto\">examiner les protocoles d&#039;essais cliniques existants et pr\u00e9vus<\/span><\/b><span data-contrast=\"auto\">\u00a0afin de garantir la conformit\u00e9 avec les exigences mises \u00e0 jour, il est conseill\u00e9 aux \u00e9quipes des affaires r\u00e9glementaires et de la recherche et d\u00e9veloppement clinique d&#039;\u00e9valuer les m\u00e9thodologies des \u00e9tudes cliniques.\u00a0<\/span><b><span data-contrast=\"auto\">\u00c9quipes d&#039;assurance qualit\u00e9 et de s\u00e9curit\u00e9 des patients<\/span><\/b><span data-contrast=\"auto\">\u00a0Il convient d\u2019\u00e9valuer les proc\u00e9dures de surveillance, les pratiques de collecte de donn\u00e9es et les processus de rapport afin de garantir la conformit\u00e9 aux nouvelles normes.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Pour les entreprises op\u00e9rant sur plusieurs march\u00e9s, le suivi de l&#039;\u00e9volution des exigences r\u00e9glementaires telles que celles \u00e9mises par le CDE peut s&#039;av\u00e9rer complexe.\u00a0<\/span><b><span data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/fr\/\">RegASK<\/a>\u00a0est une plateforme de pointe d&#039;intelligence r\u00e9glementaire et d&#039;orchestration des flux de travail bas\u00e9e sur l&#039;IA agentielle<\/span><\/b><span data-contrast=\"auto\">\u00a0qui permet aux organisations internationales op\u00e9rant dans des secteurs fortement r\u00e9glement\u00e9s, tels que les produits de consommation et les sciences de la vie, d&#039;anticiper et de g\u00e9rer des environnements r\u00e9glementaires complexes. En combinant une IA agentique avanc\u00e9e et l&#039;expertise de sp\u00e9cialistes,\u00a0<a href=\"http:\/\/regask.com\/fr\/\"><strong>RegASK<\/strong><\/a>\u00a0livre\u00a0<\/span><b><span data-contrast=\"auto\">des informations pr\u00e9dictives exploitables en temps opportun et une automatisation de bout en bout<\/span><\/b><span data-contrast=\"auto\">, rationalisant les processus de conformit\u00e9, att\u00e9nuant les risques et acc\u00e9l\u00e9rant l&#039;acc\u00e8s au march\u00e9 dans plus de 160 pays. <a href=\"http:\/\/regask.com\/fr\/\"><strong>En savoir plus <\/strong><\/a>ou<a href=\"https:\/\/regask.com\/fr\/reserver-une-demo\/\"><strong> r\u00e9servez une d\u00e9mo maintenant.<\/strong><\/a><\/span><strong>\u00a0<\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1717019643 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-840548290\">\n\n\t<div id=\"col-1062131373\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQ<\/h3>\n\t<div id=\"gap-839194292\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-839194292 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4><span class=\"TextRun MacChromeBold SCXW267956491 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW267956491 BCX0\" data-ccp-parastyle=\"heading 3\">Quelles sont les nouvelles recommandations du CDE concernant les essais cliniques des vaccins contre la grippe\u00a0?<\/span><\/span><span class=\"EOP SCXW267956491 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-431082692\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-431082692 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW27095292 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW27095292 BCX0\">Les directives publi\u00e9es par\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW27095292 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW27095292 BCX0\">Centre d&#039;\u00e9valuation des m\u00e9dicaments (CDE)<\/span><\/span><\/strong><span class=\"TextRun SCXW27095292 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW27095292 BCX0\">\u00a0le 11 mars,\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW27095292 BCX0\">2026<\/span><span class=\"NormalTextRun SCXW27095292 BCX0\">\u00a0\u00e9tablit\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW27095292 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW27095292 BCX0\">Exigences techniques relatives \u00e0 la conception, \u00e0 la r\u00e9alisation et \u00e0 l&#039;\u00e9valuation des essais cliniques de vaccins contre la grippe en Chine<\/span><\/span><span class=\"TextRun SCXW27095292 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW27095292 BCX0\">.<\/span><\/span><span class=\"EOP SCXW27095292 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1062131373 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-821277902\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW214959691 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW214959691 BCX0\" data-ccp-parastyle=\"heading 3\">Quand les directives relatives aux essais cliniques du vaccin contre la grippe entreront-elles en vigueur\u00a0?<\/span><\/span><span class=\"EOP SCXW214959691 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-383518097\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-383518097 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Les conseils <strong>est entr\u00e9 en vigueur le 11 mars 2026,<\/strong> et s&#039;applique \u00e0 <strong>tous les essais cliniques nouveaux et en cours sur les vaccins contre la grippe, initi\u00e9s en Chine \u00e0 compter de cette date. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-821277902 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-2126652522\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW3036610 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW3036610 BCX0\" data-ccp-parastyle=\"heading 3\">Quelles fonctions r\u00e9glementaires sont concern\u00e9es par cette mise \u00e0 jour\u00a0?<\/span><\/span><span class=\"EOP SCXW3036610 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-781995809\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-781995809 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>La mise \u00e0 jour a principalement un impact sur <strong>\u00c9quipes des affaires r\u00e9glementaires, de la recherche et du d\u00e9veloppement clinique, de l&#039;assurance qualit\u00e9 et de la s\u00e9curit\u00e9<\/strong> responsable du d\u00e9veloppement du vaccin contre la grippe, de la supervision des essais cliniques et des soumissions r\u00e9glementaires.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2126652522 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-171793254\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW14904628 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">Comment peut-on\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">RegASK<\/span><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">\u00a0Comment aider les organisations \u00e0 g\u00e9rer des mises \u00e0 jour comme celle-ci\u00a0?<\/span><\/span><span class=\"EOP SCXW14904628 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-352768394\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-352768394 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW233594670 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/fr\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW233594670 BCX0\">RegASK<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW233594670 BCX0\">\u00a0aide les \u00e9quipes r\u00e9glementaires et de conformit\u00e9\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW233594670 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW233594670 BCX0\">moniteur<\/span><span class=\"NormalTextRun SCXW233594670 BCX0\">\u00a0Mises \u00e0 jour r\u00e9glementaires mondiales, analyse des changements r\u00e9glementaires et rationalisation des processus de conformit\u00e9<\/span><\/span><\/strong><span class=\"TextRun SCXW233594670 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW233594670 BCX0\">\u00a0\u00e0 travers plusieurs\u00a0<\/span><span class=\"NormalTextRun SCXW233594670 BCX0\">juridictions<\/span><span class=\"NormalTextRun SCXW233594670 BCX0\">, permettant une adaptation plus rapide aux exigences \u00e9volutives telles que les nouvelles directives relatives aux essais cliniques.<\/span><\/span><span class=\"EOP SCXW233594670 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-171793254 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Le 11 mars 2026, le Centre d&#039;\u00e9valuation des m\u00e9dicaments (CDE) a publi\u00e9 des lignes directrices provisoires sur les essais cliniques des vaccins contre la grippe, pr\u00e9cisant les exigences r\u00e9glementaires actualis\u00e9es en mati\u00e8re de d\u00e9veloppement et d&#039;\u00e9valuation cliniques des vaccins en Chine. Ces lignes directrices \u00e9tablissent les exigences techniques relatives \u00e0 la conception, \u00e0 la r\u00e9alisation et \u00e0 l&#039;\u00e9valuation des essais cliniques, dans le but de soutenir la recherche scientifique et d&#039;assurer la coh\u00e9rence r\u00e9glementaire dans le d\u00e9veloppement des vaccins contre la grippe. Elles s&#039;appliquent aux organismes impliqu\u00e9s\u2026<\/p>","protected":false},"author":43,"featured_media":9663,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,514,35],"tags":[],"class_list":["post-9662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-china-regulations","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.4 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China CDE Issues Interim Guidance on Clinical Trials<\/title>\n<meta name=\"description\" content=\"Explore the China CDE interim guidance on clinical trials for influenza vaccines, essential for vaccine development and evaluation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/le-cde-chinois-publie-des-recommandations-provisoires-sur-les-essais-cliniques-des-vaccins-contre-la-grippe\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China CDE Issues Interim Guidance on Clinical Trials for Influenza Vaccines\" \/>\n<meta property=\"og:description\" content=\"Explore the China CDE interim guidance on clinical trials for influenza vaccines, essential for vaccine development and evaluation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/le-cde-chinois-publie-des-recommandations-provisoires-sur-les-essais-cliniques-des-vaccins-contre-la-grippe\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T22:23:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"China CDE Issues Interim Guidance on Clinical Trials fo&hellip;\",\"datePublished\":\"2026-03-17T22:23:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/\"},\"wordCount\":808,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png\",\"articleSection\":[\"Regulatory News\",\"China\",\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/\",\"name\":\"China CDE Issues Interim Guidance on Clinical Trials\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png\",\"datePublished\":\"2026-03-17T22:23:26+00:00\",\"description\":\"Explore the China CDE interim guidance on clinical trials for influenza vaccines, essential for vaccine development and evaluation.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png\",\"width\":800,\"height\":600,\"caption\":\"China Cde Issues Interim Guidance Clinical Trials Influenza Vaccines\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\",\"https:\\\/\\\/www.crunchbase.com\\\/organization\\\/regask\",\"https:\\\/\\\/www.bloomberg.com\\\/profile\\\/company\\\/1691237D:SP\",\"https:\\\/\\\/pitchbook.com\\\/profiles\\\/company\\\/265004-02\",\"https:\\\/\\\/www.cbinsights.com\\\/company\\\/RegASK\",\"https:\\\/\\\/vimeo.com\\\/RegASK\"],\"legalName\":\"RegASK PTE. LTD.\",\"foundingDate\":\"2018\",\"slogan\":\"Empowering Smarter Regulatory Decisions\",\"description\":\"Agentic AI regulatory intelligence and workflow orchestration platform for Life Sciences and Consumer Products. RegASK combines vertical LLMs, multi-agent AI architecture, and a global community of 1,800+ subject matter experts to deliver regulatory horizon scanning, impact analysis, compliance workflow automation, and audit-ready outputs across 160+ countries.\",\"areaServed\":\"Worldwide\",\"founder\":{\"@type\":\"Person\",\"name\":\"Caroline Shleifer\",\"jobTitle\":\"Founder & CEO\"},\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"79 Science Park Drive, #06-01, Cintech IV\",\"addressLocality\":\"Singapore\",\"postalCode\":\"118264\",\"addressCountry\":\"SG\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+65 6817 6290\",\"contactType\":\"customer service\",\"availableLanguage\":[\"English\",\"French\",\"Japanese\",\"Spanish\",\"Chinese\",\"German\"]},\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"knowsAbout\":[\"Regulatory Intelligence\",\"Regulatory Compliance\",\"Regulatory Affairs\",\"Workflow Orchestration\",\"Life Sciences Regulation\",\"Consumer Products Regulation\",\"AI-Driven Compliance\"],\"hasCertification\":[{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 42001:2023\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27001:2022\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27701\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27018:2019\"},{\"@type\":\"Certification\",\"name\":\"SOC 2 Type II\"}]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Le CDE chinois publie des recommandations provisoires sur les essais cliniques","description":"D\u00e9couvrez les recommandations provisoires du CDE chinois sur les essais cliniques des vaccins contre la grippe, essentielles pour le d\u00e9veloppement et l&#039;\u00e9valuation des vaccins.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/le-cde-chinois-publie-des-recommandations-provisoires-sur-les-essais-cliniques-des-vaccins-contre-la-grippe\/","og_locale":"fr_FR","og_type":"article","og_title":"China CDE Issues Interim Guidance on Clinical Trials for Influenza Vaccines","og_description":"Explore the China CDE interim guidance on clinical trials for influenza vaccines, essential for vaccine development and evaluation.","og_url":"https:\/\/regask.com\/fr\/le-cde-chinois-publie-des-recommandations-provisoires-sur-les-essais-cliniques-des-vaccins-contre-la-grippe\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-03-17T22:23:26+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/#article","isPartOf":{"@id":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"China CDE Issues Interim Guidance on Clinical Trials fo&hellip;","datePublished":"2026-03-17T22:23:26+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/"},"wordCount":808,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png","articleSection":["Regulatory News","China","Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/","url":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/","name":"Le CDE chinois publie des recommandations provisoires sur les essais cliniques","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png","datePublished":"2026-03-17T22:23:26+00:00","description":"D\u00e9couvrez les recommandations provisoires du CDE chinois sur les essais cliniques des vaccins contre la grippe, essentielles pour le d\u00e9veloppement et l&#039;\u00e9valuation des vaccins.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/china-cde-issues-interim-guidance-on-clinical-trials-for-influenza-vaccines\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/china-cde-issues-interim-guidance-clinical-trials-influenza-vaccines.png","width":800,"height":600,"caption":"China Cde Issues Interim Guidance Clinical Trials Influenza Vaccines"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK","https:\/\/www.crunchbase.com\/organization\/regask","https:\/\/www.bloomberg.com\/profile\/company\/1691237D:SP","https:\/\/pitchbook.com\/profiles\/company\/265004-02","https:\/\/www.cbinsights.com\/company\/RegASK","https:\/\/vimeo.com\/RegASK"],"legalName":"RegASK PTE. LTD.","foundingDate":"2018","slogan":"Empowering Smarter Regulatory Decisions","description":"Plateforme d&#039;intelligence artificielle multi-agents pour la veille r\u00e9glementaire et l&#039;orchestration des flux de travail dans le secteur des sciences de la vie et des produits de consommation. RegASK combine des LLM verticaux, une architecture d&#039;IA multi-agents et une communaut\u00e9 mondiale de plus de 1\u00a0800 experts pour fournir une veille r\u00e9glementaire, une analyse d&#039;impact, l&#039;automatisation des processus de conformit\u00e9 et des r\u00e9sultats pr\u00eats pour l&#039;audit dans plus de 160 pays.","areaServed":"Worldwide","founder":{"@type":"Person","name":"Caroline Shleifer","jobTitle":"Founder & CEO"},"address":{"@type":"PostalAddress","streetAddress":"79 Science Park Drive, #06-01, Cintech IV","addressLocality":"Singapore","postalCode":"118264","addressCountry":"SG"},"contactPoint":{"@type":"ContactPoint","telephone":"+65 6817 6290","contactType":"customer service","availableLanguage":["English","French","Japanese","Spanish","Chinese","German"]},"numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"knowsAbout":["Regulatory Intelligence","Regulatory Compliance","Regulatory Affairs","Workflow Orchestration","Life Sciences Regulation","Consumer Products Regulation","AI-Driven Compliance"],"hasCertification":[{"@type":"Certification","name":"ISO\/IEC 42001:2023"},{"@type":"Certification","name":"ISO\/IEC 27001:2022"},{"@type":"Certification","name":"ISO\/IEC 27701"},{"@type":"Certification","name":"ISO\/IEC 27018:2019"},{"@type":"Certification","name":"SOC 2 Type II"}]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/9662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=9662"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/9662\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/9663"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=9662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=9662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=9662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}